Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / HIST1H2BC

HIST1H2BC

Basics

Aliases:
This biomarker is also known as:
  • dJ221C16.3,
  • Histone H2B.l,
  • H2B.1,
  • H2B/l,
  • Histone H2B.g,
  • Histone H2B.a,
  • H2B histone family, member L,
  • H2B/a,
  • H2BFK,
  • H2BFA,
  • histone 1, H2bc,
  • Histone H2B.h,
  • histone H2B.l,
  • H2BFH,
  • H2BFG,
  • H2B/g,
  • histone H2B.1 A,
  • H2B/k,
  • histone cluster 1, H2bc,
  • H2BFL,
  • Histone H2B.k,
  • H2B/h,
  • histone H2B type 1-C/E/F/G/I,
  • Histone H2B.1 A,

View in BioMuta

Description…

From NCBI Gene: Histones are basic nuclear proteins that are responsible for the nucleosome structure of the chromosomal fiber in eukaryotes. Two molecules of each of the four core histones (H2A, H2B, H3, and H4) form an octamer, around which approximately 146 bp of DNA is wrapped in repeating units, called nucleosomes. The linker histone, H1, interacts with linker DNA between nucleosomes and functions in the compaction of chromatin into higher order structures. This gene is intronless and encodes a member of the histone H2B family. Transcripts from this gene lack polyA tails but instead contain a palindromic termination element. This gene is found in the large histone gene cluster on chromosome 6. [provided by RefSeq, Jul 2008]

Attributes

QA State: Curated
Type: Gene
Short Name:
HGNC Name: HIST1H2BC

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Prostate

Attributes

Phase: One
QA State: Curated

Overview

No additional prostate data available.

Performance Comment

Significance Analysis of Microarray (SAM) was used to develop a 7-gene classifier. The overall prediction accuracy and sensitivity is 71% and 76%, respectively. The inclusion of the Gleason sum to the seven-gene classifier raised the prediction accuracy and sensitivity to 83% and 76% respectively This prognostic signature is closely associated with biochemical recurrence in patients after radical prostatectomy. The seven genes are: RRAGD, PQBP1, HIST1H2BC, ALDH1A2, TRIM22, RBPMS, HSPB8.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

New Funding Opportunity: Biomarker Development Laboratories for the Early Detection Network: Applications Due May 23

Update: Pre-application webinar information now available.

The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.

The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.

The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.